Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia

Detalhes bibliográficos
Autor(a) principal: Conchon,Monika
Data de Publicação: 2011
Outros Autores: Freitas,Carla Maria Boquimpani de Moura, Rego,Maria Aparecida do Carmo, Braga Junior,José Wilson Ramos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012
Resumo: Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.
id ABHHTC-1_83a2052255f2ad1c0f6f3aa63d49454c
oai_identifier_str oai:scielo:S1516-84842011000200012
network_acronym_str ABHHTC-1
network_name_str Revista brasileira de hematologia e hemoterapia (Online)
repository_id_str
spelling Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapyDrug toxicityDrug interactionsGastrointestinal tract/drug effectsDrug resistance, neoplasmPyrimidinesInterferonalpha/administration & dosagePiperazines/therapeutic useClinical TrialDasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2011-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012Revista Brasileira de Hematologia e Hemoterapia v.33 n.2 2011reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.5581/1516-8484.20110034info:eu-repo/semantics/openAccessConchon,MonikaFreitas,Carla Maria Boquimpani de MouraRego,Maria Aparecida do CarmoBraga Junior,José Wilson Ramoseng2011-06-13T00:00:00Zoai:scielo:S1516-84842011000200012Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2011-06-13T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false
dc.title.none.fl_str_mv Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
title Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
spellingShingle Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
Conchon,Monika
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
Drug toxicity
Drug interactions
Gastrointestinal tract/drug effects
Drug resistance, neoplasm
Pyrimidines
Interferonalpha/administration & dosage
Piperazines/therapeutic use
Clinical Trial
title_short Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
title_full Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
title_fullStr Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
title_full_unstemmed Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
title_sort Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
author Conchon,Monika
author_facet Conchon,Monika
Freitas,Carla Maria Boquimpani de Moura
Rego,Maria Aparecida do Carmo
Braga Junior,José Wilson Ramos
author_role author
author2 Freitas,Carla Maria Boquimpani de Moura
Rego,Maria Aparecida do Carmo
Braga Junior,José Wilson Ramos
author2_role author
author
author
dc.contributor.author.fl_str_mv Conchon,Monika
Freitas,Carla Maria Boquimpani de Moura
Rego,Maria Aparecida do Carmo
Braga Junior,José Wilson Ramos
dc.subject.por.fl_str_mv Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
Drug toxicity
Drug interactions
Gastrointestinal tract/drug effects
Drug resistance, neoplasm
Pyrimidines
Interferonalpha/administration & dosage
Piperazines/therapeutic use
Clinical Trial
topic Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
Drug toxicity
Drug interactions
Gastrointestinal tract/drug effects
Drug resistance, neoplasm
Pyrimidines
Interferonalpha/administration & dosage
Piperazines/therapeutic use
Clinical Trial
description Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.
publishDate 2011
dc.date.none.fl_str_mv 2011-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5581/1516-8484.20110034
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia v.33 n.2 2011
reponame:Revista brasileira de hematologia e hemoterapia (Online)
instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
instname_str Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron_str ABHHTC
institution ABHHTC
reponame_str Revista brasileira de hematologia e hemoterapia (Online)
collection Revista brasileira de hematologia e hemoterapia (Online)
repository.name.fl_str_mv Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
repository.mail.fl_str_mv sbhh@terra.com.br||secretaria@rbhh.org
_version_ 1754213111191044096

Registros relacionados